



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

9 September 2026
EMA/CAT/221037/2026
Human Medicines Division

Committee for Advanced Therapies (CAT)

Minutes of the meeting on 12-14 August 2026 - *written procedure*

Chair: Ilona Reischl-Kok; Vice-Chair: Kieran Breen

Disclaimers

Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, these minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	5
1.1.	Adoption of agenda	5
2.	Evaluation of ATMPs	5
2.1.	Opinions	5
2.2.	Oral explanations	5
2.3.	Day 180 list of outstanding issues	5
2.4.	Day 120 list of questions	5
2.5.	Day 80 assessment reports	5
2.5.1.	Lunsotogene parvec - Orphan - EMEA/H/C/006802	5
2.6.	Update on ongoing initial applications.....	5
2.7.	New applications	6
2.8.	Withdrawal of initial marketing authorisation application	6
2.9.	Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004	6
2.10.	GMP and GCP inspections requests.....	6
2.11.	Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	6
2.12.	Extension applications.....	6
2.13.	Other Post-Authorisation Activities	6
2.14.	Companion diagnostics - initial consultation	6
2.15.	Companion diagnostics – Follow-up consultation	6
3.	Certification of ATMPs	6
3.1.	Opinion.....	6
3.2.	Day 60 Evaluation Reports.....	7
3.3.	New Applications.....	7
4.	Scientific Recommendation on Classification of ATMPs	7
4.1.	New requests – Appointment of CAT Coordinator	7
4.1.1.	Autologous CAR-T lymphocytes anti-CEACAM6	7
4.1.2.	Recombinant adeno-associated viral vector containing codon-optimised expression cassette to drive the expression of the SQ form of a B-domain deleted human coagulation APC-resistant factor VIII	7
4.1.3.	Adeno-associated virus 8 (AAV8)-based gene therapy vector expressing B domain-deleted human factor VIII (hFVIII).....	7
4.1.4.	Autologous, colorectal, tumour infiltrating, tumour-reactive lymphocytes T (TILs)	8
4.1.5.	Single-stranded, non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) encoding a micro-dystrophin gene	8
4.1.6.	Micronized autologous adipose tissue	8

4.1.7.	Micronized adipose tissue	8
4.1.8.	Extracellular vesicles derived from human induced pluripotent stem cells	8
4.1.9.	Human trophoblast stem cell-derived extracellular vesicles suspended in cross-linked hyaluronic acid hydrogel carrier	9
4.1.10.	Human trophoblast stem cell-derived extracellular vesicles impregnated into a resorbable surgical matrix scaffold	9
4.2.	Day 30 ATMP scientific recommendation	9
4.3.	Day 60 revised scientific recommendation (following list of questions)	9
4.4.	Finalisation of procedure	9
4.4.1.	Allogeneic umbilical cord-derived mesenchymal stem cells.....	9
4.4.2.	Recombinant adeno-associated virus containing the human microdystrophin gene	10
4.4.3.	Recombinant adeno-associated virus vector containing a mini-dystrophin analog (mini-UDYS) transgene	10
4.5.	Follow-up and guidance.....	10
5.	Scientific Advice	10
5.1.	New requests - appointment of CAT Rapporteurs	10
5.2.	Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs	10
5.3.	Finalisation of D70 procedures – feedback from the discussion meeting.....	10
6.	Pre-Authorisation Activities	10
6.1.	Paediatric investigation plans.....	11
6.2.	ITF briefing meetings in the field of ATMPs	11
6.3.	Priority Medicines (PRIME) – Eligibility requests.....	11
6.3.1.	Month 0 - Start of the procedure	11
6.3.2.	Month 1 – Discussion of eligibility	11
6.3.3.	Month 2 – Recommendation of eligibility.....	11
6.3.4.	Ongoing support.....	11
7.	Organisational, regulatory and methodological matters	11
7.1.	Mandate and organisation of the CAT	11
7.2.	Coordination with EMA Scientific Committees.....	11
7.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	11
7.4.	Cooperation with the EU regulatory network.....	12
7.5.	Cooperation with international regulators	12
7.6.	CAT work plan	12
7.7.	Planning and reporting	12
7.8.	Others	12

8.	Any other business	12
9.	Explanatory notes	13

1. Introduction

1.1. Adoption of agenda

The CAT agenda for 12-14 August 2026 meeting was adopted via a written procedure.

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

No items

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

2.5.1. Lunsotogene parvec - Orphan - EMEA/H/C/006802

Accelerated assessment

Regeneron Ireland Designated Activity Company; Treatment of biallelic OTOF variant-associated hearing loss in adults and children

Scope: Day 80 assessment report

Action: for information

The information was noted.

2.6. Update on ongoing initial applications

No items

2.7. New applications

No items

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

No items

2.14. Companion diagnostics - initial consultation

No items

2.15. Companion diagnostics – Follow-up consultation

No items

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

Timetable:

-Start of the procedure:	14.08.2026
-EMA Coordinator's draft report:	30.08.2026
-CAT Coordinator's comments:	02.09.2026
-Revised scientific recommendation:	04.09.2026
-CAT's discussion of scientific recommendation:	11.09.2026

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Autologous CAR-T lymphocytes anti-CEACAM6

Treatment of pancreatic ductal adenocarcinoma (PDAC) PNM I/II

Scope: ATMP scientific recommendation

Action: for nomination of CAT coordinator

The CAT coordinator was appointed.

4.1.2. Recombinant adeno-associated viral vector containing codon-optimised expression cassette to drive the expression of the SQ form of a B-domain deleted human coagulation APC-resistant factor VIII

Treatment of adults with severe or moderate haemophilia A (congenital FVIII deficiency) without anti-AAV-LK03 antibodies

Scope: ATMP scientific recommendation

Action: for nomination of CAT coordinator

The CAT coordinator was appointed.

4.1.3. Adeno-associated virus 8 (AAV8)-based gene therapy vector expressing B domain-deleted human factor VIII (hFVIII)

Treatment of haemophilia A (HA)

Scope: ATMP scientific recommendation

Action: for nomination of CAT coordinator

The CAT coordinator was appointed.

4.1.4. Autologous, colorectal, tumour infiltrating, tumour-reactive lymphocytes T (TILs)

Treatment of colorectal cancer with a single metastatic lesion

Scope: ATMP scientific recommendation

Action: for nomination of CAT coordinator

The CAT coordinator was appointed.

4.1.5. Single-stranded, non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) encoding a micro-dystrophin gene

Treatment of Duchenne muscular dystrophy

Scope: ATMP scientific recommendation

Action: for nomination of CAT coordinator

The CAT coordinator was appointed.

4.1.6. Micronized autologous adipose tissue

Adjunctive local treatment of refractory gastrointestinal fistulas to support tissue repair and fistula closure

Scope: ATMP scientific recommendation

Action: for nomination of CAT coordinator

The CAT coordinator was appointed.

4.1.7. Micronized adipose tissue

Intended for application in chronic deep anal fissures

Scope: ATMP scientific recommendation

Action: for nomination of CAT coordinator

The start of the procedure was postponed.

4.1.8. Extracellular vesicles derived from human induced pluripotent stem cells

Intended for the treatment of organ fibrosis

Scope: ATMP scientific recommendation

Action: for nomination of CAT coordinator

The CAT coordinator was appointed.

4.1.9. Human trophoblast stem cell-derived extracellular vesicles suspended in cross-linked hyaluronic acid hydrogel carrier

Intended for the regeneration and repair of periodontal and peri-implant oral tissues; suppression of senescence-associated secretory phenotype (SASP) in aged and damaged oral tissue cells; proposed use in periodontitis, peri-implantitis, post-extraction wound healing, and oral soft tissue regeneration

Scope: ATMP scientific recommendation

Action: for nomination of CAT coordinator

The CAT coordinator was appointed.

4.1.10. Human trophoblast stem cell-derived extracellular vesicles impregnated into a resorbable surgical matrix scaffold

Intended for the regeneration of periodontal, alveolar bone and peri-implant tissues following oral surgery, implantology, bone grafting and surgical extraction; suppression of post-surgical senescence-associated inflammation and promotion of tissue repair at surgical sites

Scope: ATMP scientific recommendation

Action: for nomination of CAT coordinator

The CAT coordinator was appointed.

4.2. Day 30 ATMP scientific recommendation

No items

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

4.4.1. Allogeneic umbilical cord-derived mesenchymal stem cells

Treatment of chronic kidney disease (CKD)

Scope: No comments received from the European Commission. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does fulfil the definition of a somatic cell therapy medicinal product as provided in Article 2(1) of Regulation (EC) 1394/2007.

4.4.2. Recombinant adeno-associated virus containing the human microdystrophin gene

Treatment of Duchenne muscular dystrophy (DMD)

Scope: No comments received from the European Commission. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does fulfil the definition of a gene therapy medicinal product as provided in Article 2(1) of Regulation (EC) 1394/2007.

4.4.3. Recombinant adeno-associated virus vector containing a mini-dystrophin analog (mini-UDYS) transgene

Treatment of Duchenne muscular dystrophy (DMD)

Scope: No comments received from the European Commission. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does fulfil the definition of a gene therapy medicinal product as provided in Article 2(1) of Regulation (EC) 1394/2007.

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests - appointment of CAT Rapporteurs

No items

5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs

No items

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

No items

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to

contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

No items

6.3. Priority Medicines (PRIME) – Eligibility requests

No items

6.3.1. Month 0 - Start of the procedure

No items

6.3.2. Month 1 – Discussion of eligibility

No items

6.3.3. Month 2 – Recommendation of eligibility

No items

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

No items

7.2. Coordination with EMA Scientific Committees

No items

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

No items

7.4. Cooperation with the EU regulatory network

No items

7.5. Cooperation with international regulators

No items

7.6. CAT work plan

No items

7.7. Planning and reporting

No items

7.8. Others

No items

8. Any other business

No items

Date of next CAT meeting:

09-11 September 2026

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations in Committee CMD documents and in relation to EMA regulatory activities


Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

New applications (sections 2.1. to 2.9.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures** (section 2.3). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

New applications (section 2.7.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

Withdrawal of applications (section 2.8.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

GMP and GCP Inspections Issues (section 2.10)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.11-2.13.)

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Companion diagnostics (section 2.14. & 2.15.)

This section lists applications for initial and follow-on consultation of companion diagnostics.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT.

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested

parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/